Journal
JOURNAL OF CONTROLLED RELEASE
Volume 142, Issue 2, Pages 277-285Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jconrel.2009.10.026
Keywords
Polymer therapeutics; Endotoxin neutralizer; Nanostructures; Molecular devices; Peptoid; Sepsis
Funding
- Spanish Ministry of Science and Innovation (MICINN) [BIO2007-60066, SAF2008-00048, CTQ2007-60601]
- Fundacion Centro de Investigacion Principe Felipe (CIPF)
Ask authors/readers for more resources
Sepsis is a leading cause of mortality that is most often provoked by endotoxins (i.e. lipopolysaccharides; LPS) released by Gram-negative bacteria into the patient's bloodstream during infection. The therapeutic armory currently available for sepsis treatment is poor. We previously identified an LPS-neutralizing small molecule, PTD7. Here we tested the efficacy of novel PTD7-nanoconjugates in a murine model of sepsis. We found that PTD7-based nanoconjugates treated mice had improved survival that it was correlated with a marked decrease in proinflammatory cytokines in the blood. This proves that nanoconjugate-based endotoxin neutralizers can function as intracorporeal neutralizers of bacterial endotoxins. (C) 2009 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available